O
Orlo H. Clark
Researcher at University of California, San Francisco
Publications - 404
Citations - 24266
Orlo H. Clark is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Thyroid & Thyroid cancer. The author has an hindex of 85, co-authored 404 publications receiving 23022 citations. Previous affiliations of Orlo H. Clark include Lund University & University of California.
Papers
More filters
Journal ArticleDOI
Two G protein oncogenes in human endocrine tumors
John Lyons,Claudia A. Landis,Claudia A. Landis,Griffith R. Harsh,Lucia Vallar,Kurt Grünewald,Hans Feichtinger,Quan-Yang Duh,Orlo H. Clark,Ernest S. Kawasaki,Henry R. Bourne,Henry R. Bourne,Frank McCormick +12 more
TL;DR: Findings suggest that human tumors may harbor oncogenic mutations in various G protein alpha chain genes, referred to as gip2.
Journal ArticleDOI
Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Electron Kebebew,Philip H.G. Ituarte,Allan Siperstein,Quan-Yang Duh,Quan-Yang Duh,Orlo H. Clark +5 more
TL;DR: In this article, the authors compared the predictive values of these staging or prognostic scoring systems by calculating the proportion of variance explained (PVE) for each system and found that age at presentation and stage were independent predictors of survival.
Journal ArticleDOI
Somatic and Germ-Line Mutations of the HRPT2 Gene in Sporadic Parathyroid Carcinoma
Trisha M. Shattuck,Stiina Välimäki,Takao Obara,Randall D. Gaz,Orlo H. Clark,Dolores M. Shoback,Margaret E. Wierman,Katsuyoshi Tojo,Christiane M. Robbins,John D. Carpten,Lars-Ove Farnebo,Catharina Larsson,Andrew Arnold +12 more
TL;DR: Sporadic parathyroid carcinomas frequently have HRPT2 mutations that are likely to be of pathogenetic importance, and certain patients with apparently sporadic parathyro carcinoma carry germ-line mutations in HRPT1 and may have the HPT-JT syndrome or a phenotypic variant.
Journal ArticleDOI
Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
Peter Singer,David S. Cooper,Gilbert H. Daniels,Paul W. Ladenson,Francis S. Greenspan,Elliot G. Levy,Lewis E. Braverman,Orlo H. Clark,McDougall Ir,K V Ain,S G Dorfman +10 more
TL;DR: A set of minimum clinical guidelines for use by primary care physicians in the evaluation and management of patients with thyroid nodules or thyroid cancer was developed by consensus by an 11-member Standards of Care Committee of the American Thyroid Association.
Journal ArticleDOI
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Electron Kebebew,Julie Weng,Juergen Bauer,Gustavo G.Fernandez Ranvier,Orlo H. Clark,Quan-Yang Duh,Daniel Shibru,Boris C. Bastian,Ann Griffin +8 more
TL;DR: BRAF V600E mutation is primarily present in conventional papillary thyroid cancer and is associated with an aggressive tumor phenotype and higher risk of recurrent and persistent disease in patients with conventional papilla thyroid cancer.